The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation
Brain Tumor, Primary
DRUG: HLX208
ORR, Objective response rate(assessed by independent radiological review committee (IRRC) based on the RANO, from first dose to the last patient was followed up for 6 month
PFS, Progression-free survival(PFS):assessed by IRRC and the investigator based on the RANO, from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier)，an average of about 1 year|DOR, Duration of response, from the first occurrence of a documented CR or PR (whichever recorded earlier) to the time of first documented disease progression or death (whichever occurs first)，an average of about 1 year|OS, Overall survival, from the first dose to the time of death due to any cause，an average of about 2 year
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation